Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials

BACKGROUND: The outcomes of patients diagnosed with head and neck squamous cell carcinoma (HNSCC) who are not candidates for local salvage therapy and of those diagnosed with recurrent or metastatic disease are dismal. A relatively new systemic therapy option that emerged in recent years in the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Poulose, Jissy Vijo, Kainickal, Cessal Thommachan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Systematic Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153072/
https://www.ncbi.nlm.nih.gov/pubmed/35662989
http://dx.doi.org/10.5306/wjco.v13.i5.388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153072/
https://www.ncbi.nlm.nih.gov/pubmed/35662989
http://dx.doi.org/10.5306/wjco.v13.i5.388

Ejemplares similares